QNCX
Quince Therapeutics, Inc.Company with tickers: QNCX
CIK
1662774
CUSIP
22053A107
Shares Outstanding
16,300,740
Website
https://www.quincetx.com
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $14,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $6,845,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-14,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $35,912,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $3.60 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $2.88 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |